CONGRESS GUIDE

ERS International Congress 2016
Room M Session 279 17:15 - 19:15
Industry evening symposium: NTM lung infections: challenging the current treatment approach
Organised by Insmed
Chairs : Michael Loebinger (London, United Kingdom)
17:15
NTM Overview
Michael Loebinger (London, United Kingdom)
INDUSTRY SPONSORED SESSIONS
SUNDAY 04 SEPTEMBER, 2016
1684
17:55
18:25
Recent Developments in the Treatment of NTM Lung Infections
Charles Daley (Denver, CO, United States of America)
Hide and Seek: Drugs and Bugs in the Macrophage
Jakko van Ingen (Nijmegen, Netherlands)
1686
1685
18:45 Question-and-answer
Room P Session 280 17:15 - 19:15
Industry evening symposium: New Frontiers and Clinical Advances in Immunotherapy for
Asthma:Focus on Biologics-Based Management of Moderate-to-Severe Asthma in Patients Failing
ICS and LABA
Organised by Sanofi and Regeneron Pharmaceuticals
Chairs : Sally Wenzel (Pittsburgh, United States of America), Michael Wechsler (Denver, United States of America)
17:15
Welcome: Addressing New Challenges in Asthma Management
Sally Wenzel (Pittsburgh, United States of America)
1687
17:20
17:40
18:00
18:20
18:45
Overview of Asthma Disease Burden, Epidemiology, and Spectrum of Allergic-Atopic Disorders: Where
Have We Succeeded? Where is There Room for Improvement? How Well Are Our Patients with
Asthma Really Doing?
Christopher E. Brightling (Leicester, United Kingdom)
The Unmet Need for New Therapies to Address Moderate-to-Severe Asthma in Patients Failing Inhaled
Corticosteroids (ICS) and Long-Acting Beta-Agonists (LABA): Where and Why Are Current Therapies
Failing? The Rationale for Novel Targets to Improve Clinical Outcomes in Asthma
Michael Wechsler (Denver, United States of America)
The Pathoimmunobiology of Asthma: The Rationale for Cytokine-Targeted Inhibition in Patients with
Asthma—Mechanisms of Action and Immunotherapeutic Effects of Systemic, Biologic Agents to
Manage Moderate-to-Severe Asthma
Rohit Katial (Denver, United States of America)
Results of Clinical Trials Focused on Cytokine-Targeted Inhibition in Adult Patients with Asthma:
Dosing, Outcomes, Safety and Practical Implications—What Did the TrialsTeach Us? How Do the
Results Guide Us in Biologics-Based Management? What Targets? Why? When? In Which Patient
Subgroups?
Sally Wenzel (Pittsburgh, United States of America)
Chairperson’s Summary and Near Future Vision Statement
The Near Term Future and Translational Implications of Biologic Therapy for Asthma: Meeting an
Unmet Need—When? In Whom? For How Long? A State-of-the-Art Update on Etablished and
Emerging Trends in Biologic-Based Management
Michael Wechsler (Denver, United States of America)
1688
1689
1690
1691
1692
19:00 Interactive Q&A Session 1693
Room K Session 281 17:15 - 19:15
Industry evening symposium: Disease management of COPD, AATD and NCFBE: What can we
learn from real-life data?
Organised by GRIFOLS, S.A.
Chairs : James D. Chalmers (Perth, United Kingdom)
17:15
Introduction
James D. Chalmers (Perth, United Kingdom)
1694
6 26.08.2016